Previous 10 | Next 10 |
- Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17 th , 2024 in Stockholm, Sweden - $193.3 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., May 09, 20...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
2024-05-06 20:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the following upcoming ...
2024-05-01 13:18:37 ET More on Adverum Biotechnologies Seeking Alpha’s Quant Rating on Adverum Biotechnologies Historical earnings data for Adverum Biotechnologies Financial information for Adverum Biotechnologies Read the full article on Seeking Alp...
2024-04-27 03:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present the 26-week landmark int...
2024-03-21 17:40:51 ET More on Adverum Biotechnologies Seeking Alpha’s Quant Rating on Adverum Biotechnologies Historical earnings data for Adverum Biotechnologies Financial information for Adverum Biotechnologies Read the full article on Seeking Alp...
A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 2.1% to $0.1303 on volume of 179,729,686 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 6.4% to $3.24 on volume of 152,956,858 shares PROSHARES TRUST (SQQQ) fell 1.2% to $10.3 on volume o...
A look at the top 10 most actives in the United States Yield10 Bioscience Inc. (YTEN) rose 135.5% to $0.5722 on volume of 57,300,938 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 8.7% to $3.16 on volume of 30,926,102 shares Kaival Brands Innovations Group Inc. (KAVL) rose...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
9.75%Change Percent:
Adverum Biotechnologies Inc. Company Name:
ADVM Stock Symbol:
NASDAQ Market:
Adverum Biotechnologies Inc. Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
- 6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks - Efficacy: 76% of 6E10 patients were injection free, with maintained visual acuity and fluid contr...
REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the inte...